Evidence map›Paper›PMID 38195505›Full record

ArticleReproductive biology and endocrinology : RB&E2024

Transcriptome analysis of adenomyosis eutopic endometrium reveals molecular mechanisms involved in adenomyosis-related implantation failure and pregnancy disorders.

Elena Juárez-Barber, Ana Corachán, María Cristina Carbajo-García, Amparo Faus, Carmen Vidal, Juan Giles, Antonio Pellicer, Irene Cervelló, Hortensia Ferrero

Open access · goldAbstract read
In one paragraph

Article in Reproductive biology and endocrinology : RB&E, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
9.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 17 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Divergent Associations of the VEGF (Medicina (Kaunas, Lithuania) · 2026
    Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Elena Juárez-BarberFundación IVI, Instituto de Investigación Sanitaria La Fe, Valencia, 46026, Spain.
Ana CorachánFundación IVI, Instituto de Investigación Sanitaria La Fe, Valencia, 46026, Spain.
María Cristina Carbajo-GarcíaFundación IVI, Instituto de Investigación Sanitaria La Fe, Valencia, 46026, Spain.
Amparo FausFundación IVI, Instituto de Investigación Sanitaria La Fe, Valencia, 46026, Spain.
Carmen VidalIVI-RMA Valencia, Valencia, 46015, Spain.
Juan GilesIVI-RMA Valencia, Valencia, 46015, Spain.
Antonio PellicerFundación IVI, Instituto de Investigación Sanitaria La Fe, Valencia, 46026, Spain.
Irene Cervelló *Fundación IVI, Instituto de Investigación Sanitaria La Fe, Valencia, 46026, Spain.
Hortensia Ferrero *Fundación IVI, Instituto de Investigación Sanitaria La Fe, Valencia, 46026, Spain. hortensia.ferrero@ivirma.com.
Instituto de Investigación Sanitaria La Fe · ESUniversitat de València · ESValencian Infertility Institute · ES

Funding

European Social Fund (ESF) "Investing in your future" through the Miguel Servet Program CP19/00149European Social Fund (ESF) "Investing in your future" through the Miguel Servet Program CP20/00120Generalitat Valenciana. Ministerio de Ciencia e Innovación. ACIF/2019/139Generalitat Valenciana. Ministerio de Ciencia e Innovación. APOSTD/2020/123Instituto de Salud Carlos III FI19/00110
6 · The paper itself

Abstract

backgroundWomen with adenomyosis are characterized by having defective decidualization, impaired endometrial receptivity and/or embryo-maternal communication, and implantation failure. However, the molecular mechanisms underlying adenomyosis-related infertility remain unknown, mainly because of the restricted accessibility and the difficult preservation of endometrial tissue in vitro. We have recently shown that adenomyosis patient-derived endometrial organoids, maintain disease-specific features while differentiated into mid-secretory and gestational endometrial phase, overcoming these research barriers and providing a robust platform to study adenomyosis pathogenesis and the associated molecular dysregulation related to implantation and pregnancy disorders. For this reason, we aim to characterize the dysregulated mechanisms in the mid-secretory and gestational endometrium of patients with adenomyosis by RNA-sequencing.

methodsEndometrial organoids were derived from endometrial biopsies collected in the proliferative phase of women with adenomyosis (ADENO) or healthy oocyte donors (CONTROL) (n = 15/group) and differentiated into mid-secretory (-SECorg) and gestational (-GESTorg) phases in vitro. Following RNA-sequencing, the significantly differentially expressed genes (DEGs) (FDR < 0.05) were identified and selected for subsequent functional enrichment analysis and QIAGEN Ingenuity Pathway Analysis (IPA). Statistical differences in gene expression were evaluated with the Student's t-test or Wilcoxon test.

resultsWe identified 1,430 DEGs in ADENO-SECorg and 1,999 DEGs in ADENO-GESTorg. In ADENO-SECorg, upregulated genes included OLFM1, FXYD5, and RUNX2, which are involved in impaired endometrial receptivity and implantation failure, while downregulated genes included RRM2, SOSTDC1, and CHAC2 implicated in recurrent implantation failure. In ADENO-GESTorg, upregulated CXCL14 and CYP24A1 and downregulated PGR were related to pregnancy loss. IPA predicted a significant inhibition of ID1 signaling, histamine degradation, and activation of HMGB1 and Senescence pathways, which are related to implantation failure. Alternatively, IPA predicted an inhibition of D-myo-inositol biosynthesis and VEGF signaling, and upregulation of Rho pathway, which are related to pregnancy loss and preeclampsia.

conclusionsIdentifying dysregulated molecular mechanisms in mid-secretory and gestational endometrium of adenomyosis women contributes to the understanding of adenomyosis-related implantation failure and/or pregnancy disorders revealing potential therapeutic targets. Following experimental validation of our transcriptomic and in silico findings, our differentiated adenomyosis patient-derived organoids have the potential to provide a reliable platform for drug discovery, development, and personalized drug screening for affected patients.

Indexed as

Abortion, SpontaneousAdenomyosisAdaptor Proteins, Signal TransducingEndometriumFemaleGene Expression ProfilingHumansIon ChannelsMicrofilament ProteinsPregnancyRNAAdaptor Proteins, Signal TransducingFXYD5 protein, humanIon ChannelsMicrofilament ProteinsRNASOSTDC1 protein, humanAdenomyosisEndometrial organoidsImplantation failureInfertilityPregnancy lossRNA-sequencing

Identifiers

PMID38195505
PMCPMC10775471
OpenAlexW4390760563

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.